Evogene Revenue and Competitors

Location

$94.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Evogene's estimated annual revenue is currently $21.4M per year.(i)
  • Evogene's estimated revenue per employee is $175,328
  • Evogene's total funding is $94.5M.

Employee Data

  • Evogene has 122 Employees.(i)
  • Evogene grew their employee count by -10% last year.

Evogene's People

NameTitleEmail/Phone
1
Chief AgronomistReveal Email/Phone
2
VP HRReveal Email/Phone
3
EVP TechnologyReveal Email/Phone
4
Head MicroBoost AIReveal Email/Phone
5
VP Experimental TechnologiesReveal Email/Phone
6
VP R&D AgSeedsReveal Email/Phone
7
VP Computational TechnologiesReveal Email/Phone
8
Head BioinformaticsReveal Email/Phone
9
EVP TechnologyReveal Email/Phone
10
Head Marketing and PRReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Evogene?

Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique predictive biology platform incorporating deep scientific understandings and advanced computational technologies. This platform is utilized by the Company to discover and develop innovative Ag-Chemical, Ag-Biological and Ag-Seed products (GM and non GM), and by two subsidiaries; Evofuel, focused on castor seeds, and Biomica, focused on human microbiome therapeutics. Through its collaborations with world-leading agricultural companies such as BASF, Bayer, DuPont, Monsanto and Syngenta, Evogene has licensed genes, small molecules and microbes to partners under milestone and royalty bearing agreements. For more information, please visit www.evogene.com

keywords:N/A

$94.5M

Total Funding

122

Number of Employees

$21.4M

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Evogene News

2022-04-20 - Evogene (TSE:EVGN) Receives Buy Rating from Echelon ...

Evogene (TSE:EVGN – Get Rating)'s stock had its “buy” rating reaffirmed by equities research analysts at Echelon Wealth Partners in a...

2022-04-17 - Should You Sell Evogene Ltd (EVGN) Stock Thursday?

Evogene Ltd (EVGN) stock has fallen -74.89% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.

2022-04-06 - Premarket Mover: Evogene Ltd (EVGN) Up 3.51%

Evogene Ltd (EVGN) is up 3.51% today. Overall Score - 40. EVGN has an Overall Score of 40. Find out what this means to you and get the rest of...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.5M12216%$61M
#2
$35.4M1228%N/A
#3
$27.7M12227%N/A
#4
$21M12212%N/A
#5
$19.5M1225%N/A